Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dose Finding Study Clear all
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07290062
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
INS1202
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Not listed Phase 2 Interventional

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

NCT04294004
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Fusion
Interventions
TGplPTH1-34 in fibrin, Autologous Bone Graft
Combination Product · Other
Lead sponsor
Kuros Biosurgery AG
Industry
Eligibility
25 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
La Jolla, California • Boulder, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 23, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355
View directory record Official record
Conditions
Friedreich's Ataxia (FA)
Interventions
SGT-212
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

NCT01157871
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
XRP0038 (NV1FGF), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 23, 2026, 5:06 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

NCT00225550
View directory record Official record
Conditions
Neoplasms
Interventions
ADH -1 (Exherin™)
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2007 · Synced Oct 23, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2814, Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

NCT03194217
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Parkinson Disease
Interventions
BEN-2001, Placebo
Drug
Lead sponsor
BenevolentAI Bio
Industry
Eligibility
50 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

VPD-737 for Treatment of Chronic Pruritus

NCT01951274
View directory record Official record
Conditions
Chronic Pruritus
Interventions
VPD-737, Placebo
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Fremont, California • Lomita, California • Redwood City, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional

Stage IV Colorectal CA ALIMTA

NCT00166465
View directory record Official record
Conditions
Locally Advanced Unresectable or Stage IV Colorectal Cancer
Interventions
ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 23, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02254551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LDE225, Bortezomib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Denver, Colorado • Cincinnati, Ohio • Chattanooga, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06664502
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01902225
View directory record Official record
Conditions
Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma
Interventions
Istodax, Doxil
Drug
Lead sponsor
Weiyun Ai
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

NCT00598572
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine Mesylate
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 23, 2026, 5:06 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

NCT06432166
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
2-hydroxybenzylamine acetate, Placebo
Drug · Other
Lead sponsor
MTI Biotech Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)

NCT02043665
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Bladder Cancer
Interventions
CVA21/pembrolizumab
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
9
States / cities
Santa Monica, California • Coral Gables, Florida • Niles, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY2599023 (DTX201)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

NCT02603809
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
74
States / cities
Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

NAC to Prevent Cisplatin-induced Hearing Loss

NCT02094625
View directory record Official record
Conditions
Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow

NCT01525043
View directory record Official record
Conditions
Epicondylitis of the Elbow
Interventions
Naproxen, Synera patch twice daily, Synera patch for 12hrs/day, Synera
Drug
Lead sponsor
International Clinical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy

NCT02123017
View directory record Official record
Conditions
Colonoscopy Preparation
Interventions
90 grams of Crystalline Lactulose, 135 grams of Crystalline Lactulose, 180 grams of Crystalline Lactulose
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
8 Months to 50 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 23, 2026, 5:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

NCT00635557
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
MPC-6827 + Carboplatin
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Oct 23, 2026, 5:06 AM EDT